Key facts
- Bleichroeder LP filed SCHEDULE 13G/A for Evoke Pharma, Inc. Common Shares (EVOK).
- Disclosed ownership: 10%.
- Date of event: 24 Mar 2025.
Bleichroeder LP - 24 Mar 2025 SCHEDULE 13G/A Report for Evoke Pharma, Inc. Common Shares (EVOK)
- Filing Manager
- Bleichroeder LP
- Reporting Manager
- Bleichroeder LP
- Security
- Evoke Pharma, Inc. Common Shares
- Symbol
- EVOK
- Shares outstanding
- 1,582,162 shares
- Disclosed Ownership
- 158,058 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G/A
- Filing time
- 24 Mar 2025, 18:47:51 UTC
- Date of event
- 24 Mar 2025
- Previous filing
- 21 Mar 2025
- SEC
- View on sec.gov
Key filing fact
Bleichroeder LP disclosed 10% ownership in Evoke Pharma, Inc. Common Shares (EVOK) on 24 Mar 2025.
Change
- Previous schedule filing date: 21 Mar 2025.
- Current filing was accepted on 24 Mar 2025, 18:47.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Bleichroeder LP | 10% | 158,058 | 158,058 | 0 | Andrew Gundlach | Andrew Gundlach, Chairman and CEO | |
| Bleichroeder Holdings LLC | 10% | 158,058 | 158,058 | 0 | Andrew Gundlach | Andrew Gundlach, Chairman and CEO | |
| Andrew Gundlach | 10% | 158,058 | 158,058 | 0 | Andrew Gundlach | Andrew Gundlach, Individual |
CIK / CUSIP context first